Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects marketing expenses to increase into next year to support the launch, including dissemination of two-year Phase III data after mid-2005. First Antegren patients will likely be those who have failed other therapies, CEO Mullen says